Leveraging Regulatory Collaboration to Strengthen Public–Private Innovation Partnerships
Panel discussion summary
The panel will examine how the Access Consortium can move beyond regulatory alignment to enable coordinated evidence generation, faster system adoption, and scaled innovation. It will highlight public–private partnerships that reduce duplication across regulatory, HTA, and real-world evidence pathways, improving predictability for market access.
Participants will explore cross-border RWE collaboration, stronger investor confidence, and positioning Access countries as a globally competitive innovation bloc. The session will also introduce Access Innovation BioBridge as a non-regulatory platform to drive these efforts and launch near-term pilot
Date, time and room information
Monday, May 4, 15:15 - 16:00, room Osaka/Samarkand
Moderation
| Name | Position | Institution |
|---|---|---|
| Jaspreet K. Grewal | Managing Partner | Access Innovation BioBridge |
Panelists
| Name | Position | Institution |
|---|---|---|
| Jean-Paul Lemieux | Canadian Ambassador to Switzerland and Liechtenstein | |
| Jörg Schläpfer | Chief of Staff and Head Sector External Relations | Swissmedic |
| Zara Asgharpour | Head of External Innovation | Lonza |
| Caoimhe Vallely-Gilroy | Director HealthTech Strategy and Pharma | DayOne by Basel Area Business and Innovation |
Global Village program
This panel discussion is part of the Global Village program
Host and event manager:
Logistics and marketing partner:
